A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Soo Youn Lee, Myung Hyun Nam, Soo Kim June, Jong Won Kim

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

Original languageEnglish
Pages (from-to)557-559
Number of pages3
JournalJournal of Korean medical science
Volume22
Issue number3
DOIs
Publication statusPublished - 2007

Keywords

  • Cytochrome P-450 CYP2C9
  • Pharmacogenetics
  • Polymorphism
  • Prothrombin time
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement'. Together they form a unique fingerprint.

Cite this